Monthly Archives: August 2015

20 August 2015

Parkwalk closes Xerion investment

By |August 20th, 2015|

We are pleased to announce that the University of Oxford Isis Fund II has made an investment in Xerion, a nanoparticle company spun-out of the University with a novel treatment for cancer.

Xerion seeks to commercialise Dr Helen Townley’s Research Group’s work into the use of nanoparticles in cancer for therapy, imaging and drug delivery.
The small […]

First Light Fusion – £22.7m fundraise

By |August 14th, 2015|

Parkwalk portfolio company First Light Fusion has completed a fundraising of up to £22.7 million.
First Light, a spin-out from the University of Oxford, has discovered new implosion processes that can achieve the high temperatures and compression necessary for fusion reactions and other valuable applications. The Company’s approach has the potential to dramatically shorten the […]

Parkwalk closes Quethera investment

By |August 13th, 2015|

We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in Quethera, a gene therapy company spun-out of the University with a novel treatment for glaucoma.

Quethera announces seed financing to develop gene therapy aimed at preventing blindness in glaucoma patients

CAMBRIDGE, UK, 17th September 2015: Quethera, a gene therapy […]

Xeros: update on joint development programme

By |August 11th, 2015|

Xeros Technology Group said the multi-phase joint development programme between it and LANXESS Deutschland GmbH to advance the application of Xeros’ polymer bead cleaning technology in the leather processing industry is on schedule.

Phase 1 has been concluded satisfactorily and the partnership is going to enter the next phase of technical and commercial validation as […]

Brainomix – receives Biomedical Catalyst funding to develop clinical decision-making software for stroke patients

By |August 11th, 2015|

Oxford, UK: Brainomix Limited, a developer of automated medical imaging software for neurological and cerebrovascular disorders, has been awarded £633,553 by the Biomedical Catalyst, a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support […]